Key facts
- This page summarizes Michael John Sumner's Form 4 filing for INOVIO PHARMACEUTICALS, INC. (INO).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 03 Jul 2023, 17:12.
Michael John Sumner - 30 Jun 2023 Form 4 Insider Report for INOVIO PHARMACEUTICALS, INC. (INO)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- INO
- Reported as of
- 30 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Jul 2023, 17:12:48 UTC
- Prior SEC filing
- 17 May 2023
- Next SEC filing
- 28 Feb 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Michael John Sumner
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Michael John Sumner filed Form 4 for INOVIO PHARMACEUTICALS, INC. (INO) on 03 Jul 2023.
Change
- Previous filing in this sequence was filed on 17 May 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
INO
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +35,000
- Change %
- Price
- Shares after
- 35,000
- Date
- 30 Jun 2023
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
INO
transaction
Derivative
Restricted Stock Unit
Options Exercise
- Transaction value
- $0
- Shares
- -35,000
- Change %
- -33%
- Price
- $0.000000
- Shares after
- 70,000
- Date
- 30 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,000
- Exercise price
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 105,000 restricted stock units is as follows: 35,000 shares vested on June 30, 2023; 35,000 shares will vest on June 30, 2024; 35,000 shares will vest on June 30, 2025. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both.